Company Overview
About Addition Therapeutics
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
Business Model & Competitive Advantage
The Gates Foundation's cornerstone role is the most significant signal: the foundation does not invest in biotechnology for financial returns — it invests in technologies with potential to address health challenges at global scale, particularly in low- and middle-income countries. A $100 million backing from Gates at stealth exit validates that PRINT's platform has credibility beyond rare Western diseases, likely targeting conditions like infectious disease, anemia, or metabolic disorders where gene therapy could have massive population-level impact.
Competitive Landscape 2025–2026
The re-dosable nature of PRINT is its core clinical advantage: all existing AAV gene therapies are one-time treatments because the immune system mounts an antibody response that prevents re-dosing. PRINT's LNP delivery avoids viral capsid immunogenicity, theoretically enabling booster dosing as needed — a critical advantage for diseases where a single gene therapy dose may not provide lifetime correction.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Addition Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Addition Therapeutics has achieved $100M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Addition Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Addition Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Addition Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Addition Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →